Patients with the triple negative breast cancer (TNBC) subtype, characterized by the absence of ER, progesterone receptor (PR), and human epidermal growth factor receptor-2/neu receptors (HER2/neu) have a poor prognosis [5, 6] also due to the few clinical treatments available. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.